Objective-Biological and physical factors interact to modulate blood response in a wounded vessel, resulting in a hemostatic clot or an occlusive thrombus. Flow and pressure differential (ΔP) across the wound from the lumen to the extravascular compartment may impact hemostasis and the observed core/shell architecture. We examined physical and biological factors responsible for regulating thrombin-mediated clot growth. Approach and Results-Using factor XIIa-inhibited human whole blood perfused in a microfluidic device over collagen/ tissue factor at controlled wall shear rate and ΔP, we found thrombin to be highly localized in the P-selectin + core of hemostatic clots. Increasing ΔP from 9 to 29 mm Hg (wall shear rate=400 s −1 ) reduced P-selectin + core size and total clot size because of enhanced extravasation of thrombin. Blockade of fibrin polymerization with 5 mmol/L Gly-Pro-Arg-Pro dysregulated hemostasis by enhancing both P-selectin + core size and clot size at 400 s −1 (20 mm Hg). For whole-blood flow (no Gly-Pro-Arg-Pro), the thickness of the P-selectin-negative shell was reduced under arterial conditions (2000 s −1 , 20 mm Hg). Consistent with the antithrombin-1 activity of fibrin implicated with Gly-Pro-Arg-Pro, anti-γ′-fibrinogen antibody enhanced core-localized thrombin, core size, and overall clot size, especially at venous (100 s −1 ) but not arterial wall shear rates (2000 s −1 ). Pathological shear (15 000 s −1 ) and Gly-Pro-Arg-Pro synergized to exacerbate clot growth. Conclusions-Hemostatic clotting was dependent on core-localized thrombin that (1) triggered platelet P-selectin display and (2) was highly regulated by fibrin and the transclot ΔP. Also, γ′-fibrinogen had a role in venous but not arterial conditions. (Arterioscler Thromb Vasc Biol. 2015;35:645-654. The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
D uring hemostasis, stable clot formation at the site of wounding is facilitated by the growth of a platelet plug and the generation of fibrin. Essential to vascular integrity, this structure must form rapidly under flow at an injury site, withstand hemodynamic forces, and prevent pressure-driven blood loss. With the laser injury mouse model, the in vivo architecture of the hemostatic clot has been revealed to contain 2 distinct regions of platelet activation: an inner tightly packed core with extensive α-granule release and an unstable outer shell with minimal α-granule release. 1 α-Granule release is identified by P-selectin display and is characteristic of the core. Recent mouse studies have shown that the core region is thrombin and fibrin rich, platelet retracted with lower porosity and reduced albumin mobility, and localized to the interior of the clot closest to the injury site. In contrast, the shell region is thrombin and fibrin poor, more porous, and localized to the exterior of the clot toward the vessel lumen, and displays significant platelet turnover. [1] [2] [3] [4] The regional heterogeneity of platelet activation in clots highlights the complexities of when and where agonists are localized and what biochemical and physical parameters regulate hemostatic clot development. Importantly, the factors that trigger wall-attached clots to become fully occlusive thrombi are not fully understood, but may include platelet hyper-reactivity, dysregulated thrombin production, and enhanced von Willebrand factor function in pathological stenotic flows. [5] [6] [7] Thrombin is a potent platelet activator at ≈1 nmol/L and cleaves fibrinogen to drive fibrin polymerization at ≈10 nmol/L or higher. In humans, the γ-chain of fibrinogen has 2 expression variants: γA (main form) and γ′ (splice variant). The γ′chain contains a 20-amino acid extension because of alternative mRNA splicing. 8 Unique to γ′-fibrinogen is a high-affinity binding site for exosite II on thrombin. 9 While γA/γ′ fibrinogen only makes up ≈8% to 15% of total fibrinogen, γ′-fibrinogen can serve as a sink for locally produced thrombin. [10] [11] [12] Using microfluidics and human blood, our prior studies have demonstrated that fibrin polymerization stabilizes clots by anchoring the clot to the injury site with ≈12to 28-fold greater resistance to shear forces. 13 Our goal was to study the impact of fibrin(ogen)'s antithrombin properties and fibrin March 2015 polymerization on thrombin-mediated clot growth in human blood. Mouse models do not allow precise control of prevailing shear rates, transthrombus pressure drops, or biochemical constituents of the wound. Additionally, mice lack the high-affinity thrombin-binding site on the γ′ splice variant of fibrinogen. 14 To study fibrin(ogen)'s role in the hemostatic growth of thrombi, it was critical to have reproducible hemodynamics. There are few studies that demonstrate the ability to simultaneously measure and control wall shear rate and transclot pressure gradients (ΔP). This limitation motivated our previous work on designing a microfluidic device capable of independently controlling both wall shear rate and ΔP. 15, 16 Throughout the work described, we were able to control both venous and arterial shear rates at pressure gradients (9-30 mm Hg) that have been reported in vivo. 17, 18 Using this device, we have now studied the localization of thrombin, the role of thrombin in platelet P-selectin display, and the role of fibrin polymerization and γ′-fibrinogen in regulating fibrin function. We report that fibrin, in addition to stabilizing clot structures against shear forces, 13 is critical in localizing and restricting thrombin to the core region of a hemostatic clot.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Microfluidic Device for Investigating Clot Architecture at Controlled Wall Shear Rates and Transthrombus Pressure Gradients
Thrombi were developed in vitro using a microfluidic device ( Figure 1A ). Clot formation was initiated when Corn trypsin inhibitor (CTI) whole blood was perfused across a postscaffold region loaded with collagen/tissue factor (TF; Figure 1B ). The architecture of the developing clot was investigated from a side-view perspective at independently controlled wall shear rates and transclot pressure gradients. Clots formed within this microfluidic device on collagen/TF scaffolds demonstrated distinct P-selectin-positive and -negative areas ( Figure 1C ). The P-selectin-positive region (core) remained localized to
Nonstandard Abbreviations and Acronyms CTI
Corn trypsin inhibitor GPRP Gly-Pro-Arg-Pro PPACK Phe-Pro-Arg-chloromethylketone TF tissue factor TXA 2 thromboxane A2 Figure 1 . Human thrombi develop a core and shell architecture that mimics the architecture of clots developed in vivo. Anticoagulated whole blood was perfused at a constant wall shear rate (Q 1 ), while the transthrombus pressure gradients (ΔP) were independently controlled via downstream buffer infusion Q 2 (A). Polymerized collagen±tissue factor (TF) was localized to a postscaffold centered between pressure ports P 2 and P 1 (B). Spatial and temporal thrombus development was monitored by side-view imaging at controlled wall shear rates and ΔP. Platelet (red) and P-selectin (green) antibodies (anti-CD41 and anti-CD62P) were used to investigate spatial differences in platelet activation under physiological flow conditions (n=3; C). A fluorogenic, thrombin-cleavable substrate Boc-VPR-AMC was added to whole blood to demonstrate localized thrombin activity within clots developed in the presence of ΔP (n=3; D). Human clots developed in vitro (n=4; E) and mouse clots developed in vivo (n=3 mice, 13 clots; F) were outlined by imaging the clots using platelet (blue) and P-selectin antibodies (red). A heat map was used in both images to illustrate the localization of thrombin sensor cleavage (light blue=low intensity and white=high intensity). CTI indicates Corn trypsin inhibitor.
the interior of the clot, closest to the collagen/TF surface. The P-selectin-negative region (shell) enclosed the interior core region and remained exposed to the flowing whole blood. We investigated thrombin activity with the soluble thrombin activity peptide Boc-VPR-AMC. Our results illustrated that the highest thrombin activity was located within the core region ( Figure 1D ). In agreement with these results was the cleavage of the stationary thrombin-sensing antibody ( Figure 1E ). We have previously reported the ability of our device to generate these core/shell architectures, which have only been observed in vivo. 1, 16 Recently, thrombin was revealed as the primary agonist responsible for core development in vivo during mouse arteriole laser injury. [1] [2] [3] [4] Qualitatively, cleavage of the thrombinsensing antibody within human and mouse clots is localized within the core ( Figure 1E and 1F ). This is the first report of thrombin localization to the core region of human blood clots. Using this microfluidic device allowed us to investigate the core and shell architecture of human blood clots under controlled hemodynamic conditions, a feature that is not possible in vivo.
Transthrombus Pressure Gradients Influence Thrombin-Mediated Clot Growth at 400 s −1
Thrombin-mediated clot growth was investigated by perfusing CTI-treated whole blood over a collagen/TF scaffold at 400 s −1 . Transthrombus pressure gradients were maintained at either a low (9.0 mm Hg) or high ΔP (29.4 mm Hg), both physiologically relevant pressure gradients. 17, 18 Total platelet area was calculated at each time point over the duration of the experiment (t=10.8 minutes). Clots developing at lower ΔP (9.0 mm Hg) experienced faster initial growth (≈3.8-fold faster, t=0-1.8 minutes, P<0.05) and larger final heights (≈1.5fold larger, t=10.5 minutes, P<0.025) than clots experiencing higher ΔP (29.4 mm Hg; Figure 2A ). The percentage of the total clot area that was P-selectin + (core) was 57% at both low (platelet area=12 682 μm 2 ; P-selectin + [core] area=7207 μm 2 ) and high ΔP (platelet area=8579 μm 2 ; P-selectin + [core] area=4843 μm 2 ; Figure 2B ). While the percentage of the clot that was core remained constant, final core area was reduced by 33% (P<0.05) when ΔP was increased. Similar trends were observed when measurements were made with a thrombinsensing antibody. 19 Final thrombin area was reduced by 43% (P<0.05) when ΔP was increased 3.2-fold ( Figure 2C ). This result indicates that the elution of inner clot thrombin to the surface of the clot was met with opposition by pressure-driven permeation of fluid through the clot, toward the extravascular space (the collagen postarray). When transclot pressure drops were increased, the permeation-mediated transport through the clot also increased proportionately. This reduced thrombin transport toward the clot surface to result in a smaller core area. Without thrombin generation, core size was smaller and generated at a slower rate ( Figure I in the online-only Data Supplement). Thrombin and P-selectin area were highly correlated both spatially and temporally at low ΔP (R 2 =0.91) and high ΔP (R 2 =0.95; Figure 2D ). Experiments were ended after 11 minutes of perfusion because steady-state growth was achieved and the dynamics of the system were captured prior to the final time point ( Figure II in the online-only Data Supplement). Reducing the permeation by decreasing ΔP results in greater flux of thrombin from the collagen/TF interface through the clot toward the lumen, thus resulting in a larger P-selectin-positive core at lower ΔP.
Fibrin Polymerization Reduces Both Total Platelet and Core Area at 400 s −1
Fibrin polymerization has been recognized as an important step in clot stabilization and the prevention of embolic events. 13 Beyond this role, less is known about what impact fibrin polymerization may have on clot architecture and regulation of clot growth rate. To study these effects on thrombus growth and architecture, we added Gly-Pro-Arg-Pro (GPRP), a fibrin polymerization inhibitor. Whole blood anticoagulated with CTI was incubated with and without GPRP prior to perfusion (400 s −1 ) over a collagen/TF surface. All clots were developed in the presence of a constant transthrombus pressure gradient (control−ΔP=20±0.7 mm Hg; GPRP−ΔP=20±0.5 mm Hg). Thrombus growth and architecture (P-selectin, fibrin) were monitored dynamically for 10.5 minutes of perfusion. Total platelet area and clot height grew to a greater extent when fibrin polymerization was inhibited by 5 mmol/L GPRP ( Figure 3A ). After 3 minutes of growth, clots formed in the presence of polymerized fibrin were statistically smaller (P<0.05) than clots formed without polymerized fibrin. Disparity between clot size became even greater after 5.25 minutes (P<0.025). Final clot height (t=10.5 minutes) was 67% (P=4.95×10 −5 ) larger when fibrin polymerization was inhibited. Accompanying total clot growth was an increase in core area ( Figure 3B ). P-selectin-positive area grew 2-fold larger (P=0.003) when fibrin polymerization was absent. As expected, fibrin polymerization, as measured by a fibrin-specific antibody, was completely abolished by 5 mmol/L GPRP ( Figure 3C ). There were no observable effects of GPRP on total clot or core area when thrombin activity and fibrin polymerization were prevented with Phe-Pro-Arg-chloromethylketone (PPACK; Figure III in the online-only Data Supplement).
Wall Shear Rate Does Not Influence the Core or Thrombin Area But Does Influence the Role of Fibrin
Because our device facilitated independent control of both wall shear rate and transthrombus pressure gradients, we investigated clot architecture at constant ΔP (20 mm Hg) for 3 shear rates (100 s −1 , 400 s −1 , 2000 s −1 ) ranging from venous to arterial flows. Total clot, core, thrombin, and shell area were measured for 10.5 minutes of whole-blood perfusion. The final area (t=10.5 minutes) for each was reported at the 3 distinct shear rates ( Figure 4A ). Interestingly, wall shear rate did not significantly alter the core or thrombin area when the transclot ΔP was held constant at 20 mm Hg. The only significant change that wall shear rate influenced was the shell size.
The shell size was greatest at a venous shear rate of 100 s −1 as compared with 400 s −1 (P=0.026) and 2000 s −1 (P=0.007). This increased shell thickness resulted in an increase in total clot size at 100 s −1 (P=0.009 for 400 s −1 ; P=0.015 for 2000 s −1 ). These outcomes indicated that shear rate only influences shell size while the transthrombus pressure gradient influences both core and thrombin boundary size (Figures 2 and 4) .
Clots in the presence of GPRP were developed in parallel with control clots for each shear rate. The blockade of fibrin polymerization on total clot, core, thrombin, and shell area was investigated at the final time point (t=10.5 minutes; Figure 4B ). Based on our previous results at 400 s −1 (Figure 3 ), we expected GPRP blockade of fibrin . Fibrin polymerization reduces clot growth at a wall shear rate of 400 s −1 and ΔP=20 mm Hg. Platelet area (n=7, anti-CD41 antibody, A) was measured in the absence (control) and presence (5 mmol/L Gly-Pro-Arg-Pro [GPRP]) of fibrin polymerization inhibitor GPRP at a constant transthrombus pressure gradient (ΔP=20 mm Hg) and wall shear rate (400 s −1 ). P-selectin (n=7, B) and fibrin (n=4, C) area were monitored for each condition during 10.5 minutes of Corn trypsin inhibitor whole-blood perfusion. Anti-CD62P and the fibrin-specific antibody (T2G1) were used to measure the P-selectin and fibrin area, respectively. polymerization to enhance clot height and core area at both venous and arterial shear rates. This expectation was confirmed for an arterial shear rate of 2000 s −1 ( Figure 4C ). The addition of GPRP significantly increased total clot area (1.45-fold for 400 s −1 , 1.5-fold for 2000 s −1 ) because of a drastic increase in core area (2.0-fold for 400 s −1 , 1.65fold for 2000 s −1 ). The increase in core area was directly proportional to a significant increase in thrombin area at both 400 s −1 (108% increase) and 2000 s −1 (87% increase). Interestingly, clots developed at the venous shear rate of 100 s −1 did not increase in total clot, core, or thrombin area when fibrin polymerization was inhibited with GPRP. These results indicated that thrombin regulation in venous clots is not governed by fibrin polymerization.
γ′-Fibrin(ogen) Reduces Thrombin-Mediated Clot Growth at Venous Shear Rates But Not Arterial Shear Rates
To further investigate the role of fibrin(ogen) in venous and arterial clot growth, we added a monoclonal γ′-fibrinogenspecific antibody to inhibit the high-affinity thrombin-binding site on γ′-fibrinogen ( Figure IV in the online-only Data Supplement). Antibodies were incubated in CTI whole blood at a 1:1 molar ratio to 0.3 mg/mL γ′ fibrinogen, a physiologically relevant whole-blood concentration. 20 Buffer and γ′ antibody-treated samples were perfused simultaneously at both 100 s −1 and 2000 s −1 . The final glycerol concentration in both the buffer and the γ′ antibody-treated whole blood was 170 mmol/L, which is below the threshold for observed platelet effects. 21 Total clot, core, and thrombin area were measured dynamically at a constant transclot ΔP (buffer ΔP=15.5 mm Hg, γ′ antibody ΔP=15.7 mm Hg). Clots formed at the venous shear rate of 100 s −1 had significantly increased total clot area, core area, and thrombin area when the high-affinity thrombin-binding site on γ′ fibrinogen was blocked ( Figure 5 , first column). Total clot area after 11.25 minutes of wholeblood perfusion was 2.0-fold larger (P=0.019) in the presence of the γ′ fibrinogen antibody. This increase in total clot area was associated with faster core (1.5 minutes) and thrombin generation (1.25 minutes) and larger final areas (core, 1.8fold; thrombin, 1.6-fold). Conversely, there were no significant differences between thrombi formed at the arterial shear rate of 2000 s −1 (Figure 5 , second column).
Arterial Shear Rates Promote Increased Platelet Packing, Greater Thrombin Retention, and More Fibrin Generation per Area Than Venous Shear Rates
Because clots formed at venous and arterial shear rates demonstrated inverse growth patterns when fibrin polymerization or the high-affinity thrombin-binding site on γ′ fibrinogen were blocked, we hypothesized that clot composition may influence fibrin(ogen)'s role in thrombin regulation. We investigated platelet packing density ( Figure 6A ), densitycorrected thrombin sensor cleavage ( Figure 6B ), and fibrin packing density ( Figure 6C ) by comparing clots formed in CTI whole blood at 100 s −1 to those formed at 2000 s −1 . Representative images at the final time point (t=11.5 minutes) demonstrated increased platelet packing at 2000 s −1 as compared with 100 s −1 . Likewise, density-corrected thrombin sensor cleavage and fibrin packing density were also increased at arterial shear rates (2000 s −1 ) as compared with venous shear rates (100 s −1 ). The fold increase in platelet packing density as measured by platelet fluorescence intensity per area was on average 1.83-fold higher at 2000 s −1 than 100 s −1 ( Figure 6D ). After normalizing the thrombin sensor fluorescence intensity for platelet density, the results indicated that more sensor was cleaved in arterial clots than venous clots (1.4-fold). This provides a lower estimate for the relative increase in thrombin activity in arterial clots compared with venous . Wall shear rate does not change the core or thrombin area but does influence thrombin-mediated clot growth in the absence of fibrin polymerization. Total, core (p-sel + ), thrombin, and shell (p-sel − ) areas were measured, at the final time point (t=10.5 minutes), for clots developed at a constant pressure gradient (ΔP=20 mm Hg) and varying wall shear rate (100 s −1 , 400 s −1 , 2000 s −1 ; n=4 for each shear rate; A). Corn trypsin inhibitor whole blood in the presence of 5 mmol/L Gly-Pro-Arg-Pro (GPRP; fibrin polymerization inhibitor) was run in parallel at all experimental conditions (n=4 for each shear rate; B). The fold increase in area with the addition of 5 mmol/L GPRP was calculated for total, core, thrombin, and shell area (C). Total platelet and P-selectin + area were measured with antibodies specific for anti-CD41 and anti-CD62P, respectively. Thrombin area was measured with a thrombin-sensing antibody, and the shell area was calculated as the difference between the total platelet area and the P-selectin + area.
clots. Supporting this estimate was the increased generation of fibrin in arterial clots (2.36-fold). The reduction in platelet and fibrin density within venous clots as compared with arterial clots may be because of the increased incorporation of erythrocytes in venous clots ( Figure V in the online-only Data Supplement). These results demonstrated a drastic and important difference in the composition of clots formed at arterial or venous shear rates.
Fibrin Polymerization Reduces Clot Growth at Pathological Shear Rates
In pathophysiology, wall shear rates can reach 100 000 s −1 in stenosed vessels. 22 We investigated clot formation in a scenario similar to vessel stenosis by stepping the wall shear rate up from an initial venous shear rate of 200 s −1 to a pathological shear rate of 15 000 s −1 . Clots were formed in PPACK whole blood at 200 s −1 for 7 minutes before stepping the shear rate ≤15 000 s −1 for an additional 7.75 minutes ( Figure 7A-7C ). After the increase to pathological shear rates, rapid platelet aggregation at the upstream edge of the clot resulted in a low-shear regime prior to the trailing edge of the clot. The rapid growth facilitated clot contraction at the downstream edge of the thrombus ( Figure 7C ). This could be a result of ADP and thromboxane A2 (TXA 2 ) accumulating in the low-shear regime, a phenomena which we previously documented when shear rates were reduced. 15 In this experiment, the contraction toward the center of the clot was not prevented, even at 15 000 s −1 .
The role of fibrin polymerization was also investigated at pathological shear rates. Whole blood anticoagulated with either CTI or PPACK was perfused across a collagen/TF or collagen surface, respectively. Experiments were performed simultaneously with both control-and GPRP-treated samples to evaluate the role of fibrin polymerization. The blood was initially perfused at an arterial shear rate of 2000 s −1 . After 5.4 minutes, the wall shear rate was increased to a pathological shear rate of 15 000 s −1 for the remaining 5.8 minutes of the experiment. The inhibition of fibrin polymerization with GPRP in CTI whole blood resulted in increased clot growth for both arterial and pathological shear rates ( Figure 7D ). The average clot height of GPRP clots was 73.2% larger after 5.4 minutes of flow at 2000 s −1 (P=0.006) and 152.4% larger after an additional 5.8 minutes of flow at 15 000 s −1 (P=0.001). In contrast, PPACK whole-blood clots did not demonstrate a significant increase (P>0.05) with the addition of GPRP at either arterial or pathological shear rates ( Figure 7E ). This demonstrated that the mechanism by which GPRP is enhancing clot growth is dependent on fibrin polymerization which is subsequent to thrombin generation.
Discussion
The clots developed in our device utilizing human blood ( Figure 1C-1E ) closely matched the architecture of clots developed in vivo ( Figure 1F ). When the device was operated at a constant wall shear stress, we observed that transthrombus pressure gradients could regulate the core and thrombin heights. Reducing transthrombus pressure gradients resulted in an increase in the core and thrombin heights, leading to larger total clot heights. In this scenario, pressure-driven permeation through the clot toward the extravascular space was reduced when ΔP was reduced. This decrease in permeation toward the extravascular space allows for thrombin diffusion through the clot toward the lumen. As the thrombin boundary grew, the core region grew. In turn, this may result in an increase in ADP and TXA 2 release as demonstrated by P-selectin exposure. Because ADP and TXA 2 are soluble small molecules and diffuse much faster than thrombin (D ADP =50×10 −11 m 2 /s>> D Thrombin =8×10 −11 m 2 /s), they facilitated shell growth by recruiting additional platelets to the surface of the clot (Figure 8) . 23, 24 We demonstrated that the core/shell architecture was present throughout the development of human blood clots under physiological conditions of hemostasis over an ex vivo wound of collagen/TF. The sensitivity of the core and shell development was investigated by independently controlling the wall shear rate (100 s −1 to 2000 s −1 ) and transthrombus pressure gradient (ΔP=9.0-29.4 mm Hg). Fibrin polymerization reduced thrombin-mediated clot growth at arterial but not venous shear rates. This can be explained by our observation of increased platelet and fibrin packing at arterial shear rates as compared with venous shear rates. The influence of the shear rate on clot structure and composition became more evident when γ′fibrinogen's high-affinity thrombin-binding site was inhibited with a monoclonal antibody. When clots were developed at venous shear rates (decreased packing density) and the highaffinity thrombin-binding site on γA/γ′ was inhibited, the size of the total clot, thrombin, and core increased.
We also demonstrated that the shell region is dependent on the local shear rate at the surface of the clot whereas the core region is only a dependent on the transthrombus pressure gradient. These results agree with the governing role of transport rates within and around the developing clot. The low permeability of thrombi places an emphasis on both convective and diffusive transport within the clot, while the transport at the surface of the clot is governed by the local wall shear rate (con vection>>diffusion). 16 This means that thrombin, which has a much slower diffusion rate than ADP or TXA 2 , requires the protection of the clot to effectively diffuse. Conversely, the diffusive transport rates of ADP and TXA 2 are fast and can compete with larger convective forces that are present near the surface of the clot. This is why shell growth has been directly correlated with ADP and TXA 2 . 1 So, when surface convection rates are low, such as venous shear rates, ADP and TXA 2 diffusion plays a larger role in platelet recruitment. This role is diminished at arterial shear rates which causes reduced shell growth. These results define the physical parameters that govern clot development and the resulting core and shell architecture of human clots.
Another important aspect of clot development is fibrin formation. To study fibrin's role, we examined the packing density of platelets and fibrin within human thrombi formed at venous or arterial shear rates. We found that increasing the shear from a venous to an arterial rate results in an increase in both platelet and fibrin packing. This increase in platelet and fibrin density may be a result of the lower erythrocyte incorporation within clots developed under arterial shears ( Figure V in the online-only Data Supplement). Recent work has demonstrated that increased erythrocyte incorporation can act to form an impermeable seal after clot contraction. 25 Our Figure 6 . Clots formed at arterial shear rates pack tighter, cleave more thrombin-sensitive peptide per area, and generate more fibrin per area than venous clots. Corn trypsin inhibitor whole blood was perfused simultaneously at a venous shear rate of 100 s −1 and an arterial shear rate of 2000 s −1 . Platelet (A), normalized thrombin sensor (B), and fibrin fluorescence intensity (C) were imaged for 11.5 minutes. The fold increase in platelet fluorescence intensity per area (n=6) from clots formed at 100 s −1 compared with 2000 s −1 was averaged over the duration of the experiment (D). In addition, the density-corrected thrombin sensor cleavage (n=6) and fibrin fluorescence intensity (n=3) were calculated and compared for venous and arterial clots. Platelet, thrombin, and fibrin fluorescence were measured with an anti-CD41 antibody, thrombin-sensing antibody, and fibrin-specific antibody (T2G1), respectively. FI indicates fluorescence intensity.
work suggests that this mechanism may play a larger role in venous thrombi. We also found an increase in thrombin activity at arterial shears. These results supported previous work performed in vivo, which described the majority of fibrin formation as being contained within the densely packed core. 1, 2, 4 Complementary in silico investigations using the porosities of the tightly packed core and loosely packed shell illustrated thrombin retention within the core region because of the lower porosity decreasing the effective diffusion of thrombin. 3 To determine how fibrin contributes to the formation of a dense clot microenvironment, we formed clots in the presence of GPRP to prevent fibrin polymerization. Our results demonstrated a drastic increase in thrombin, core, and total platelet area when fibrin polymerization was inhibited with GPRP at arterial shear rates. The same increase was not observed at venous shear rates, where clot porosity was elevated and fibrin density was reduced. At arterial shears, our results are consistent with increased thrombin diffusion because of a lack of fibrin leading to an increased area of activity. However, in the case of clots generated at venous shear rates that have high porosity, we propose that the reduced fibrin facilitated rapid convective removal of thrombin through the injury site. As a result, the removal of fibrin polymerization facilitated even greater thrombin removal, causing mild reductions in total and thrombin area. We hypothesized that thrombin diffusion toward the vessel lumen may also be limited by binding rather than just physical hindrance.
We investigated this hypothesis by preventing thrombin binding to the high-affinity binding site on the γ′-chain of fibrinogen. The γ′-chain has been implicated as a new clinical biomarker for acute events and chronic diseases such as myocardial infarctions, coronary artery disease, and deep vein thrombosis. 20, 26, 27 Studies have shown that thicker fibrin fibers (low thrombin concentrations) have more γ′-binding sites than thinner fibrin fibers (high thrombin concentrations). 28 These reports, coupled with our thrombin sensor cleavage results, predict greater γ′-thrombin binding at venous shear rates rather than arterial shear rates because of the differences in the fibrin network. When we blocked the high-affinity binding site on the γ′-chain of fibrinogen with a monoclonal antibody, we saw significant increases in total clot, thrombin, and core area only at venous shear rates. This suggests that at venous shear rates, fibrinogen preferentially binds thrombin using the γ′-chain of fibrinogen to inhibit thrombosis. Conversely, the low porosity and increased fibrin present in arterial clots prevent thrombin boundary growth by physically limiting the diffusion of thrombin. While thrombin binding to γA/γ′ is still present at arterial shear rates, it alone cannot prevent . Clot growth at pathological shear rates was abated by fibrin polymerization. Phe-Pro-Argchloromethylketone (PPACK) whole blood (WB) was perfused across a collagen scaffold at 200 s −1 . Clot formation was imaged with a fluorescent platelet-specific monoclonal antibody (red, anti-CD41; A). After 7 minutes of perfusion, the shear rate was increased to a pathological shear rate of 15 000 s −1 . Images of clot formation were taken at t=10.75 minutes (B) and t=14.75 minutes (C). Zones of low shear, caused by rapid platelet aggregation upstream, often formed and contracted at the trailing edge of the developing clot. In a similar experiment, either Corn trypsin inhibitor (CTI) or PPACK WB was perfused over a collagen/tissue factor (TF) or collagen surface, respectively. Perfusion was initially at 2000 s −1 prior to stepping the shear ≤15 000 s −1 . Control conditions were compared with Gly-Pro-Arg-Pro (GPRP)-treated samples with inhibited fibrin polymerization. Clot height was recorded throughout the duration of the experiment (D). Average clot heights were calculated for both the control and GPRP samples. The measurements were made for both CTI (n=4 each condition) and PPACK (n=4 each condition) treated WB both before and after increasing the shear rate (E; *P<0.01).
or promote arterial thrombosis as demonstrated by previous in vivo work. 29 These results complement the requirement of fibrin polymerization at arterial and not venous shear rates.
Interestingly, clots formed at pathological shear rates were also dependent on fibrin polymerization for regulated growth. We investigated this dependence by increasing the wall shear rate from an arterial shear rate (2000 s −1 ) to a pathological shear rate (15 000 s −1 ) that might be found in a stenosed vessel. When the control samples were compared with the GPRP-treated samples, the results demonstrated that fibrin polymerization was responsible for the reduction in clot growth at pathological shear rates. This regulation was in alignment with our results at arterial shears. Increasing the shear rate from an arterial to pathological rate increases the dependence on platelet-von Willebrand factor interactions. 30 In this case, fibrin limits thrombin-mediated platelet recruitment and may also interfere with platelet-vonWillebrand factor interactions necessary for growth at pathological shears. This is evident by the increased growth in PPACK samples void of fibrin. This mechanism may be protective in the event of a ruptured plaque where TF exposure and shear rates are high. 31 In a similar experiment, the wall shear rate was increased from a venous shear and whole blood was anticoagulated with PPACK. The clot grew rapidly, at the leading edge, when shears were increased to pathological rates. This rapid growth created a zone of low shear which facilitated the local accumulation of soluble agonists such as ADP and TXA 2 , as we have previously demonstrated. 15 This enabled the downstream edge of the clot to contract, a flow-sensing response to anchor the clot to the collagen scaffold. The contraction in the opposite direction of a pathological shear rate of 15 000 s −1 was strong enough to prevent embolization in the absence of fibrin.
While the venous and arterial clots in this study were investigated at the same ΔP, lower vessel pressures are often found in venous circulation as compared with arterial circulation. 32 This reduction in vessel pressure may decrease the pressure drop across the developing clot, which would allow greater thrombin boundary growth and fibrin formation. The increase in fibrin formation along with the trapping of red blood cells gives venous clots the label of red clot. On the other hand, arteries often have a higher vessel pressure than veins which may increase the transthrombus pressure gradient which would decrease clot retention of thrombin and the formation of fibrin. This reduction in fibrin and the high concentration of platelets give arterial clots the label of white clot. As we have demonstrated, these changes in transthrombus pressure gradients would increase the role of thrombin binding via γ′ fibrinogen and decrease fibrin's role in hindering thrombin diffusion because of the resulting increase in convective removal. These observations illustrate the complex balance of both physical and biochemical parameters that influence the development of clots (Figure 8 ).
These results have numerous clinical implications, particularly in venous and arterial thrombosis. Recent reports of interest have shown that interleukin-6 disproportionately increases the expression of γ′ as compared with γA. 33 Elevated interleukin-6 levels are associated with increased risk of future myocardial infarction. 34 The increase in γ′-chain fibrinogen seems to be a mechanism for protection, at least in the venous circulation. Our results in this study did not indicate any protective effects within clots generated at arterial conditions but did show protective effects at venous shear rates. This may explain why lower γ′ levels have been implicated as a deep vein thrombosis risk. 27 Future work to determine the function of the core/shell architecture and role of γ′-fibrinogen in different pathophysiologies will be required to advance and improve patient care.
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